Latest Conference Coverage

Takeaways, Highlights From the Institutional Perspectives in Neurology: MS: Eric Klawiter, MD, MSc

The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]

Black Patients Present Greater Association With Comorbidities Prior to Ischemic Stroke

There was no significant association between Black race and clinical outcome following mechanical thrombectomy.

Discussing Novel Imaging Outcomes in Multiple Sclerosis: Eric Klawiter, MD, MSc

The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital outlined a presentation he gave at a recent Institutional Perspectives in Neurology: MS event. [WATCH TIME: 3 minutes]

Significance and Role of B-Cell Depleting Medications for Multiple Sclerosis

Kristin Galetta, MD, MSEd, provided insight on differences between B-cell depleting disease-modifying therapies for MS and how they continue to shape the future of drug development.

Interim Analysis Finds No Safety Concerns for SELECT2 Trial in Acute Ischemic Stroke

The data safety monitoring board reviewed 90-day outcomes for the first 200 patients, recommending that investigators continue the study as it currently stands.

Massachussets General Hospital: Institutional Perspectives in Neurology, Chaired by Eric Kawiter, MD, MSc

Chaired by Eric Klawiter, MD, MSc, the presentations also feature Mass General and Brigham and Women's experts Tanuja Chitnis, MD; Kristin Galetta, MD; and Michael Levy, MD, PhD. [WATCH TIME: 1 hour, 26 minutes]

Understanding Differences in B-Cell Depleting Medications for MS: Kristin Galetta, MD, MSEd

The professor of neurology at Brigham and Women’s Hospital discussed her presentation on B-cell depleting therapies such as ocrelizumab and ofatumumab for the treatment of multiple sclerosis. [WATCH TIME: 2 minutes]

Tenecteplase Restores Blood Flow Up to 24 Hours Post-Stroke With Limited Hemorrhage Risk

More than 30% of the lower dose tenecteplase group achieved major reperfusion without symptomatic intracranial hemorrhage at 24 to 48 hours after thrombolysis.

EVT Reduces Physical Limitations, Improves 90-Day Outcomes Over Standard Therapy in Severe Stroke

A greater proportion of those treated with EVT had modified Rankin Scale scores of 0-3 at 90 days and NIHSS improvements of at least 8 points or more at 48 hours, relative to standard medical therapy.

Poor Outcomes Observed for Children With Untreated Large Vessel Occlusion Stroke

For pediatric patients with LVO, 4 out of 5 fulfilled adult thrombectomy selection criteria, aside from age.

Telestroke Implementation, Standardized Workflow Facilitate Equitable Endovascular Treatment

DOAC Treatment a Reasonable Alternative to Warfarin for Patients With CVT

When compared with warfarin, treatment with DOACs was associated with a favorable safety profile, as well as similar clinical and radiographic outcomes in patients with cerebral venous thrombosis.

Deep Learning Algorithm Shows High Accuracy in Predicting ICH Hematoma Expansion

The artificial neural network demonstrated an area under the precision-recall curve of 0.92 with recall of 0.72 with precision of 0.39 during testing, all values that were greater than classic regression models.

Eptifibatide During Endovascular Therapy May Increase Risk of Parenchymal Hematoma Hemorrhage in LVO Stroke

After small studies suggested eptifibatide may be safe in acute ischemic stroke, new data showed similar rates of ICH between study drug and controls, but increased PH-2 for those treated with the antiplatelet.

Low-Dose Ticagrelor Safe, Effective for Neuroendovascular Patients Resistant to Clopidogrel

Results from the retrospective chart review were presented at the 2020 International Stroke Conference, held in New Orleans and virtually.

Stroke-Related Inpatient Morality Increased During COVID-19 Pandemic

Relative to pre-pandemic era, the odds of mortality in stroke-related admissions increased during the pandemic, with an even greater risk for those less than 70 years of age.

How MR Fingerprinting Can Improve Epilepsy Surgery: Irene Wang, PhD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting. [WATCH TIME: 3 minutes]

Expanding the Use of Seizure Apps for Epilepsy: Jessica Fesler, MD, MEd

The staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]

Use of Seizure Apps During the Pandemic, Need for Data: Jessica Fesler, MD, MEd

Capabilities and Limitations of Seizure Apps: Jessica Fesler, MD, MEd

The staff epileptologist at Cleveland Clinic’s Epilepsy Center detailed the benefits seizure apps provide for patients with epilepsy, as well as the barriers that limit them. [WATCH TIME: 3 minutes]

NeuroVoices: Irene Wang, PhD, on the Future of MR Fingerprinting and its Impact on Epilepsy Surgery

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided an inside look at the ways MR fingerprinting can provide real-time clinical benefit for physicians and patient care.

Advantages and Potential of MR Fingerprinting in Epilepsy, Neurology: Irene Wang, PhD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed opportunities for MR fingerprinting to expand, both in the epilepsy field and in general neurology. [WATCH TIME 3 minutes]

Improving Recognition, Diagnosis of Psychogenic Nonepileptic Seizures: Becky Tilahun, PhD

Using Radiomics-Based MR Fingerprinting to Detect Focal Cortical Dysplasia: Irene Wang, PhD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided insight on her study presented at AES 2021, which showed that MR fingerprinting can differentiate focal cortical dysplasia from healthy tissue. [WATCH TIME: 4 minutes]

NeuroVoices: Irene Wang, PhD, on the Clinical Utility of MR Fingerprinting in Epilepsy

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed why MR fingerprinting holds significant clinical potential in epilepsy and epilepsy-related disorders.

Newborn Screening, mTOR Pathway May Offer New Hope for Tuberous Sclerosis

Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, discussed the idea behind swiftly treating tuberous sclerosis at infant stages using targeted therapeutic approaches.

Utilizing MR Fingerprinting to Benefit Epilepsy Care: Irene Wang, PhD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided background on the momentum behind MR fingerprinting and its potential in epilepsy care. [WATCH TIME: 3 minutes]

Tailoring Cognitive Behavioral Therapy to PNES, Seizure-Related Disorders, Becky Tilahun, PhD

The clinical psychologist at Cleveland Clinic discussed the process for successfully changing and tailoring different cognitive behavioral therapy approaches to treat various forms of seizures. [WATCH TIME: 3 minutes]

Preventing TSC By Treating at the Earliest Stage: Darcy Krueger, MD, PhD

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the thought behind STOPS2, a trial aimed at preventing or delaying seizure onset in tuberous sclerosis complex. [WATCH TIME: 3 minutes]

Treatment Optimization of Antiseizure Medications, Holding Higher Standards: William Rosenfeld, MD

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]